Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 8.10
0.00 (0.00%)
At close: Sep 3, 2026
Abera Bioscience AB Revenue
Abera Bioscience AB had revenue of 1.56M SEK in the quarter ending June 30, 2026, a decrease of -63.63%. This brings the company's revenue in the last twelve months to 9.10M, down -42.15% year-over-year. In the year 2025, Abera Bioscience AB had annual revenue of 11.85M, down -18.99%.
Revenue (ttm)
9.10M
Revenue Growth
-42.15%
P/S Ratio
18.25
Revenue / Employee
1.52M
Employees
6
Market Cap
166.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.85M | -2.78M | -18.99% |
| Dec 31, 2024 | 14.63M | 12.11M | 479.60% |
| Dec 31, 2023 | 2.52M | 736.19K | 41.18% |
| Dec 31, 2022 | 1.79M | 609.91K | 51.78% |
| Dec 31, 2021 | 1.18M | 422.43K | 55.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 136.17M |
| Xbrane Biopharma AB | 83.30M |
| Biovica International AB | 13.49M |
| NextCell Pharma AB | 10.78M |
| Elicera Therapeutics AB | 7.79M |
| Xintela AB | 3.03M |
| Simris Group AB (PUBL) | 1.39M |
| Diamyd Medical AB | 432.00K |
Abera Bioscience AB News
- 15 days ago - Abera Bioscience AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Abera Bioscience AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Abera Bioscience AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Abera Bioscience AB Annual report: Q4 2025 - Filings
- 9 months ago - Abera Bioscience AB Quarterly report: Q3 2025 - Filings